The article addresses this. There's some risk of misclassification, but the answer is the same either way: you monitor the condition carefully to see how it behaves.
The problem then is, if you rename the "grade 1" condition "prostate dysplasia", some fraction of patients don't do the follow-ups, and then those misclassifications are a big deal. But if you don't rename it, some fraction of patients get unnecessary treatment that lowers their quality of life.
The problem then is, if you rename the "grade 1" condition "prostate dysplasia", some fraction of patients don't do the follow-ups, and then those misclassifications are a big deal. But if you don't rename it, some fraction of patients get unnecessary treatment that lowers their quality of life.
So it's an interesting dilemma.